LONDON, UK, 26 June 2012 – The Intellectual Property & Science division of Thomson Reuters released its
annual synopsis of pharmaceutical industry trends today in its 2012 Pharmaceutical R&D Factbook, compiled
by CMR International, a Thomson Reuters business. Key findings include the observation that the
pharmaceutical industry’s recent emphasis on quality over quantity is working, as evidenced by a lower
number of early phase projects and fewer phase III projects being terminated, combined with an increase in
regulatory approvals.

- Global Pharmaceutical Sales Highest Ever: Global pharma sales reached an all-time high of
approximately $880 billion in 2011; with pharmaceutical companies reinvesting anywhere from two
percent to 25 percent of sales in prescription drug (or “ethical drug”) R&D. Nevertheless, the rate of
growth is declining as key drugs come off patent and the generic market grows

- Most New Molecular Entities (NMEs) Launched in Last Decade: The number of NMEs launched
are at a ten-year high (increasing to 31). Regulators and payers are looking for safer, more effective
and differentiated drugs given the large influx of generics. The industry is seeing the first signs of the
response by Pharma to increased R&D hurdles in the selection of drug candidates that are focused
on diseases with high unmet medical need and, in many cases, targeted at stratified groups of
patients (so called personalized medicine). This refocus is welcomed by the regulators and payers
as reflected by the increased number of drug launches

- Cancer treatment benefitting from advances in personalized medicine: Anti-cancer
development continues to attract the highest amount of investment across all therapeutic areas; with
recent personalized medicine advances yielding two important oncology drug approvals in 2011 with
companion diagnostics for targeted patient populations

- A marked turn in Phase III success: In the last three years we have seen a notable increase in
phase 3 project success rates

- More targeted therapies: An increase in biologics in pharma R&D with higher clinical success rates
and slower decline from peak sales, as well as an improvement in translating innovations in
biological understanding from lab to patient

“The pharmaceutical industry touches all of our lives, whether directly or indirectly. Having insight into the
drivers of the outcomes in Pharma R&D is critical in planning strategies and operational improvements,” said
Jon Brett-Harris, executive vice president, Thomson Reuters. “This year’s Factbook provides a unique view
into the industry at a point when many pharma leaders are developing new strategies for growth. It unveils our thought-leaders’ findings from extensive and proprietary data and is a valuable resource for clinical
operations, project management, portfolio managers, licensing executives, venture capitalists, and
pharmaceutical executives alike.”

Information published in the Factbook was compiled by our Life Sciences Professional Services team; it is
based on proprietary primary sources, competitive intelligence, and public sources covering key trends in the
pharmaceutical industry.

About CMR International

CMR International, a Thomson Reuters business, is the world leader in global pharmaceutical R&D
performance measurement. For over 15 years, CMR International has worked with the leading global
pharmaceutical companies to assess R&D productivity and provide insights into industry trends in order to
strengthen planning and effectiveness of R&D. Since 2003, CMR International has published the
pharmaceutical R&D Factbook, an annual report for the pharmaceutical R&D sector providing a reliable
source of key reference metrics.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and
professionals. We combine industry expertise with innovative technology to deliver critical information to
leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science
and media markets, powered by the world's most trusted news organization. With headquarters in New York
and major operations in London and Eagan, Minnesota, Thomson Reuters employs approximately 60,000
people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.